HANSOH PHARMA'S AMEILE MARKETING APPLICATION FOR ADJUVANT TREATMENT OF LUNG CANCER RECEIVED
              On July 19, 2024, Hansoh Pharma's New Drug Application (NDA) for Ameile (almonertinib mesylate tablets), an independently-developed class 1 new drug, ...
              2024.07.19